Average Dose of Foquest for Adolescents
I cannot provide dosing information for Foquest (methylphenidate) as the evidence provided contains no FDA label or prescribing information for this specific formulation. The drug label evidence 1 refers to a tetanus-diphtheria (Td) vaccine, not Foquest, which appears to be a data error in the source materials.
What the Evidence Actually Shows About Methylphenidate Dosing in Adolescents
Based on available research on methylphenidate formulations in adolescents aged 12-18 years:
Typical Dose Ranges
For adolescents over 12 years, the average optimal daily dose is approximately 46 mg/day (0.81 mg/kg/day), which is significantly higher than younger children 2. This comes from a multi-site study specifically examining dose titration in Korean children and adolescents.
- Younger adolescents (10-14 years): Average 26.8 ± 14.0 mg/day 3
- Older adolescents (>12 years): Average 46.4 ± 15.5 mg/day (0.81 ± 0.28 mg/kg/day) 2
Recent Network Meta-Analysis Findings
The most recent and comprehensive evidence 4 from 2026 analyzing 48 trials found:
- Optimal methylphenidate dose range for maximum net clinical benefit: 18-46 mg/day
- Peak benefit occurs at 30-39 mg/day
- Efficacy plateaus at approximately 45 mg/day
- Higher doses increase adverse event-related discontinuation without additional benefit
Important Clinical Considerations
Age matters more than weight for dosing. Adolescents require higher absolute doses but lower weight-adjusted doses compared to younger children 2, 5. The evidence shows:
- Older age groups need significantly higher doses (p<0.01) 2
- Girls receive slightly higher doses than boys at follow-up 5
- Adolescents with underweight have higher discontinuation rates 5
Special Adolescent Concerns from Guidelines
The AAP guideline 6 emphasizes adolescent-specific issues but does not provide specific dosing:
- Driving coverage: Longer-acting formulations or late-afternoon short-acting medications should provide symptom control while driving
- Diversion risk: Monitor for misuse or diversion of medication
- Substance use screening: Required before initiating treatment
Critical Gap
Without the actual Foquest FDA label, I cannot provide the manufacturer's recommended starting dose, titration schedule, or maximum dose for this specific extended-release formulation. Different methylphenidate formulations have different pharmacokinetics and approved dosing regimens that may not align with the general methylphenidate data presented above.